First-in-Human trial tests 'Supercharged' immune cells to hunt lymphoma
NCT ID NCT03602157
Summary
This is a first-in-human study to test the safety of a new type of engineered immune cell therapy for adults with specific lymphomas that have returned or not responded to prior treatments. Researchers modify a patient's own T-cells to better recognize and attack cancer cells carrying a marker called CD30. The main goal is to find a safe dose, as this is an early-phase trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.